Zelira Therapeutics Limited (ZLDAF)
USD 0.3
(-10.08%)
USD 0.3
(-10.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -36.56 Million AUD | -556.18% |
| 2023 | -5.57 Million AUD | 53.35% |
| 2022 | -11.94 Million AUD | -39.73% |
| 2021 | -8.54 Million AUD | -21.87% |
| 2020 | -7.01 Million AUD | -96.62% |
| 2019 | -3.56 Million AUD | -106.25% |
| 2018 | -1.72 Million AUD | 71.91% |
| 2017 | -6.15 Million AUD | -585.19% |
| 2016 | -898.63 Thousand AUD | -124.61% |
| 2015 | -400.08 Thousand AUD | -37.86% |
| 2014 | -290.21 Thousand AUD | 6.93% |
| 2013 | -311.84 Thousand AUD | 51.12% |
| 2012 | -637.95 Thousand AUD | -9181.25% |
| 2011 | 7025.00 AUD | 100.42% |
| 2010 | -1.68 Million AUD | 91.67% |
| 2009 | -20.27 Million AUD | -260.69% |
| 2008 | 12.61 Million AUD | 133.06% |
| 2007 | -38.16 Million AUD | -4133.93% |
| 2006 | -901.33 Thousand AUD | -189.2% |
| 2005 | -311.66 Thousand AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -17.06 Million AUD | -643.47% |
| 2024 Q2 | -34.13 Million AUD | -100.0% |
| 2024 FY | -36.56 Million AUD | -556.18% |
| 2024 Q3 | -1.21 Million AUD | 96.43% |
| 2024 Q4 | -1.21 Million AUD | 0.0% |
| 2023 Q2 | -3.27 Million AUD | -100.0% |
| 2023 Q1 | -1.63 Million AUD | 75.46% |
| 2023 FY | -5.57 Million AUD | 53.35% |
| 2023 Q3 | -1.14 Million AUD | 64.98% |
| 2023 Q4 | -2.29 Million AUD | -100.0% |
| 2022 FY | -11.94 Million AUD | -39.73% |
| 2022 Q1 | -2.63 Million AUD | 46.85% |
| 2022 Q2 | -5.26 Million AUD | -100.0% |
| 2022 Q3 | -3.33 Million AUD | 36.59% |
| 2022 Q4 | -6.67 Million AUD | -100.0% |
| 2021 Q1 | -1.79 Million AUD | 59.52% |
| 2021 FY | -8.54 Million AUD | -21.87% |
| 2021 Q3 | -2.47 Million AUD | 31.09% |
| 2021 Q4 | -4.95 Million AUD | -100.0% |
| 2021 Q2 | -3.59 Million AUD | -100.0% |
| 2020 Q3 | -2.21 Million AUD | 13.79% |
| 2020 FY | -7.01 Million AUD | -96.62% |
| 2020 Q1 | -1.28 Million AUD | 14.43% |
| 2020 Q2 | -2.57 Million AUD | -100.0% |
| 2020 Q4 | -4.43 Million AUD | -100.0% |
| 2019 FY | -3.56 Million AUD | -106.25% |
| 2019 Q1 | -1.03 Million AUD | -67.3% |
| 2019 Q2 | -1.03 Million AUD | 0.0% |
| 2019 Q3 | -752.37 Thousand AUD | 27.06% |
| 2019 Q4 | -1.5 Million AUD | -100.0% |
| 2018 Q4 | -616.57 Thousand AUD | 0.0% |
| 2018 Q3 | -616.57 Thousand AUD | -148.3% |
| 2018 Q2 | -248.32 Thousand AUD | 0.0% |
| 2018 Q1 | -248.32 Thousand AUD | 55.26% |
| 2018 FY | -1.72 Million AUD | 71.91% |
| 2017 Q1 | -2.52 Million AUD | 0.0% |
| 2017 FY | -6.15 Million AUD | -585.19% |
| 2017 Q4 | -555.04 Thousand AUD | 0.0% |
| 2017 Q3 | -555.04 Thousand AUD | 78.01% |
| 2017 Q2 | -2.52 Million AUD | 0.0% |
| 2016 FY | -898.63 Thousand AUD | -124.61% |
| 2015 FY | -400.08 Thousand AUD | -37.86% |
| 2014 FY | -290.21 Thousand AUD | 6.93% |
| 2013 FY | -311.84 Thousand AUD | 51.12% |
| 2012 FY | -637.95 Thousand AUD | -9181.25% |
| 2011 FY | 7025.00 AUD | 100.42% |
| 2010 FY | -1.68 Million AUD | 91.67% |
| 2009 FY | -20.27 Million AUD | -260.69% |
| 2008 FY | 12.61 Million AUD | 133.06% |
| 2007 FY | -38.16 Million AUD | -4133.93% |
| 2006 FY | -901.33 Thousand AUD | -189.2% |
| 2005 FY | -311.66 Thousand AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -754.413% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 51.217% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -13275.507% |
| SQZ Biotechnologies Company | -79.46 Million USD | 53.981% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -1164.313% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 169.025% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 156.145% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1908.698% |
| Marizyme, Inc. | -65.34 Million USD | 44.039% |
| Genus plc | 7.9 Million USD | 562.898% |
| Pharming Group N.V. | -10.54 Million USD | -246.69% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -1585.347% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -885.623% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -313.488% |
| ContraFect Corporation | -65.15 Million USD | 43.872% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -2016.924% |
| IMV Inc. | -36.48 Million USD | -0.228% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -353.726% |
| ONE Bio Corp. | 8.67 Million USD | 521.465% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 29.256% |
| Mesoblast Limited | -87.95 Million USD | 58.424% |
| MultiCell Technologies, Inc. | -380.07 USD | -9621523.385% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -879.612% |
| Genscript Biotech Corporation | -95.47 Million USD | 61.699% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -5682.495% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -1435.947% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -456.087% |
| Biomind Labs Inc. | -1.21 Million USD | -2911.474% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1078.97% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -362.716% |
| Skye Bioscience, Inc. | -37.64 Million USD | 2.858% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1776.051% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -235.749% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -244083.387% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -648.433% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -423.697% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -130.407% |
| Accustem Sciences Inc. | -3.74 Million USD | -876.103% |
| EV Biologics, Inc. | -1.26 Million USD | -2785.954% |
| Q BioMed Inc. | -2.05 Million USD | -1682.03% |
| GB Sciences, Inc. | -1.36 Million USD | -2585.578% |
| Alpha Cognition Inc. | -13.77 Million USD | -165.52% |
| CSL Limited | 2.64 Billion USD | 101.384% |
| Agentix Corp. | -1.37 Million USD | -2561.084% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 38.772% |
| Enzolytics Inc. | -2.17 Million USD | -1579.914% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -912.989% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1053.071% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -528.628% |
| argenx SE | -295.05 Million USD | 87.606% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 41.582% |
| HST Global, Inc. | -146.21 Thousand USD | -24911.219% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 37415.208% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1983.97% |
| Halberd Corporation | -79.67 Thousand USD | -45797.013% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 628.102% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1108.436% |
| Zenith Capital Corp. | -10.59 Million USD | -245.12% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -820.437% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -782.042% |
| AVAX Technologies, Inc. | -6.41 Million USD | -470.173% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -60403.863% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1723.781% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -157239.747% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -666.774% |
| Helix BioMedix, Inc. | -1.05 Million USD | -3362.777% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -857.552% |
| Kadimastem Ltd | -3.3 Million USD | -1005.67% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -331.085% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -8185.336% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2638.36% |
| LadRx Corporation | 400.44 Thousand USD | 9232.112% |
| Cell Source, Inc. | -5.32 Million USD | -587.229% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -8701.625% |
| Regen BioPharma, Inc. | 1.02 Million USD | 3672.899% |
| Regen BioPharma, Inc. | 1.02 Million USD | 3672.899% |
| Affymax, Inc. | -14.42 Million USD | -153.528% |
| Mobile Lads Corp. | -2.26 Million USD | -1515.74% |
| Itoco Inc. | -1.86 Million USD | -1856.608% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -723.154% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -2091.067% |
| International Stem Cell Corporation | -131 Thousand USD | -27815.194% |
| CytoDyn Inc. | -49.84 Million USD | 26.629% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -46170.424% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -15930.064% |
| Qrons Inc. | -789.34 Thousand USD | -4532.805% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -3783.991% |
| SYBLEU INC | -180.3 Thousand USD | -20181.804% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1651.651% |
| Rebus Holdings, Inc. | -1.02 Million USD | -3485.187% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -2167.506% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -67280.793% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -1345.27% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 23.929% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -1629.844% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -4582.996% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1054.321% |
| Neutra Corp. | -233.46 Thousand USD | -15563.549% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -80.222% |
| PureTech Health plc | -65.69 Million USD | 44.337% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -71.955% |
| IXICO plc | -1.17 Million USD | -3004.321% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -268.378% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 35.988% |
| CSL Limited | 2.64 Billion USD | 101.384% |
| Cellectis S.A. | -103.17 Million USD | 64.556% |